MSTN and cirrhosis of liver: Owing to the potent inhibitory role of MSTN on muscle growth, there has been much interest in MSTN-blocking as a strategy to treat muscle atrophy caused by chronic diseases such as cancer, kidney failure, obstructive pulmonary disease, cardiomyopathy, liver cirrhosis, and age-associated sarcopenia [5–7].